The global Microfluidics Market is expected to reach USD 10
billion by 2024, according to a new report by Grand View Research, Inc. The
demand for this sector is expected to upsurge due to the introduction of
improved technology, such as digital microfluidics, which enables on-chip
biochemical analysis.
Industry players are
introducing newer sampling technologies to meet the demand for screening a huge
number of biological samples. For instance, in March 2014, Dolomite launched
Mitos Dropix capable of generating miniature droplets to isolate contents. The
patented droplet picking technology enables high-throughput sample screening.
Moreover, researchers are
continuously striving to come up with improved sample droplet production
techniques. For instance, Columbia University introduced the picoliter fluid
dispensation technology. This lab-on-chip technology could deliver sample
volume less than 50 nL. Integrating microfluidics with multiplexed sensing
technology allows multiple sample analytical application.
Further Key Findings From the Study Suggests:
- In Vitro Diagnostic (IVD) segment dominated the
application segment owing to the increasing adoption of microfluidics in
this market. Moreover, the leaders in the diagnostics sector, such
as Abbott, Roche, and Danaher are encouraging the use of newer
microfluidics technologies, such as the monodisperse bubbles/drops.
- Novel drug delivery system requires the
administration of the drug in the form of nanoparticles, thereby reducing
the onset of action. Devices such as microneedles, pumps, and inhalers are
expected to experience fastest growth during the forecasted period.
- Polymers had the largest revenue share in 2015.
Polymers offer better temperature control as compared to glass. However,
silicon material is expected to witness fastest growth owing to the
dominance of point-of-care diagnostics in the microfluidics market. Moreover,
the growing demands for faster results with minimally invasive tools are
expected to boost growth of this sector.
- North America dominated the market in 2015. It
is attributed to the presence of strong research capital, introduction of
improved sample volume screening techniques, and presence of dominant
market players.
- In June 2016, Roche received 510 (K) clearances
for Elecsys BRAHMS PCT assay. With this launch, Roche became the only
company to offer integrated solutions: the assessment and management of
sepsis risk. The biomarker was developed to offer a solution for the 1.6
million annual hospitalizations.
- Asia Pacific is expected to witness fastest
growth owing to the increasing aging population, repeated hospital visits,
presence of untapped market, and the low cost of labor. These factors have
attracted many international players to establish their research laboratories
in India and China.
- The industry is also experiencing many mergers
and acquisitions between competitors. In July 2015, IDEX Corporation
acquired CIDRA Precision Services, LLC. CIDRA Precision Services, LLC is a
manufacturer of microfluidics devices and the acquisition is expected to
accelerate IDEX growth in the microfluidics space.
- Some key players are Illumina, Inc.; Agilent
Technologies; Caliper Life Sciences (acquired by PerkinElmer, Inc.);
Cepheid; Danaher Corporation; Life Technologies Corporation (acquired by
Thermo Fisher Scientific, Inc.);Bio-Rad Laboratories, Inc.; Abbott
Laboratories; F. Hoffmann-La Roche Ltd; and Fluidigm Corporation.
Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/microfluidics-market
No comments:
Post a Comment